The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-11. Anything still debated is marked as such rather than presented as settled.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
As of August 13, 2020, the menu underwent another update as part of their efforts to streamline processes in their restaurants in response to the COVID-19 pandemic, discontinuing the following items: Grilled Steak Soft Taco; 7-Layer Burrito; Nachos Supreme; Beefy Fritos Burrito; Spicy Tostada; Triple Layer Nachos; Cheesy Fiesta Potatoes; Loaded Grillers, both Cheesy Potato and Beefy Nacho; Chips & Dips; and Mini Skillet Bowl.
Endothelin 1 (ET-1), also known as preproendothelin-1 (PPET1), is the most potent vasoconstrictor produced by the human body. It is a peptide produced by vascular endothelial cells, as well as by cells in the heart (affecting contractility) and kidney (affecting sodium handling). The protein encoded by this gene – EDN1 – is proteolytically processed to release endothelin 1. Endothelin 1 is one of three isoforms of human endothelin.
An estimated 1,680 million people died of infectious diseases in the 20th century and about 10 million in 2010. The World Health Organization collects information on global deaths by International Classification of Disease (ICD) code categories. The following table lists the top infectious disease by number of deaths in 2002. 1993 data is included for comparison.
Differences in gene expression are especially clear within multicellular organisms, where cells all contain the same genome but have very different structures and behaviors due to the expression of different sets of genes. All the cells in a multicellular organism derive from a single cell, differentiating into variant cell types in response to external and intercellular signals and gradually establishing different patterns of gene expression to create different behaviors. Within eukaryotes, there exist structural features of chromatin that influence the transcription of genes, often in the form of modifications to DNA and chromatin that are stably inherited by daughter cells. These features are called "epigenetic" because they exist "on top" of the DNA sequence and retain inheritance from one cell generation to the next. Because of epigenetic features, different cell types grown within the same medium can retain very different properties. Although epigenetic features are generally dynamic over the course of development, some, like the phenomenon of paramutation, have multigenerational inheritance and exist as rare exceptions to the general rule of DNA as the basis for inheritance.
The Communist Chinese captured 39 P-51s from the Nationalists while they were retreating to Taiwan. In August 1949, the People's Liberation Army Air Force formed its first P-51 squadron at Beijing Nanyuan Airport and were tasked of the defending Beijing's airspace from Nationalist Air Force aircraft. On 1 October 1949, when Mao Zedong proclaimed the founding of the People's Republic of China, nine P-51s conducted a fly-past during the military parade in Beijing. By 1950, when Soviet Union began supplying modern military equipment to China, surviving P-51s were relegated to PLAAF's aviation school and 13 P-51s were modified as two-seat trainers. By September 1953, most P-51s were retired from service and only eight P-51s remained in service to teach Ilyushin Il-10 pilots on how to taxi aircraft. Costa Rica The Costa Rican Air Force flew four P-51Ds from 1955 to 1964. Cuba In November 1958, three US-registered civilian P-51D Mustangs were illegally flown separately from Miami to Cuba, on delivery to the rebel forces of the 26th of July Movement, then headed by Fidel Castro during the Cuban Revolution. One of the Mustangs was damaged during delivery and none of them were used operationally. After the success of the revolution in January 1959, with other rebel aircraft plus those of the existing Cuban government forces, they were adopted into the Fuerza Aérea Revolucionaria. Due to increasing US restrictions and lack of spares and maintenance experience, they never achieved operational status.
Sources: en.wikipedia.org
== Entrepreneurial Activities == In 2000 Gerngross co-founded Glycofi, Inc. and served as the company's Chief Scientific Officer until its acquisition by Merck & Co. in the spring of 2006. In the fall of 2006 Dr. Gerngross joined SV Life Sciences as a venture partner where he advises on investments in the bio-therapeutics area. SV Life Sciences manages five investment funds with an aggregate capital of about $1.6 billion. In 2007 Dr. Gerngross co-founded Adimab LLC. with Prof. Dane Wittrup at MIT and Errik Anderson to develop a novel platform for the discovery of human antibodies in yeast. Gerngross stepped down from heading Adimab in February 2023, and was replaced by lawyer Philip Chase. To date the company has raised five rounds of venture financing from Polaris Ventures, SV Life Sciences, Google Ventures, OrbiMed Advisors, and Borealis Ventures and employs about 70 people in Lebanon, New Hampshire. In 2020, Gerngross cofounded Adagio as a spinout of Adimab which was developing a treatment for COVID-19. In Feb. 2022, Tillman Gerngross resigned as head of the company amid concerns about the efficacy of the drug. The company changed its name to Invivyd and broadened its focus in September 2022. There is currently a pending case of fraud against Tillman related to Adagio in Massachusetts, filed January 2023. In January 2022, Gerngross introduced a new company, Amagma, which also focused on developing antibodies. Amagma was folded in 2023, and the status of its assets are unknown.
In the context of brass musical instruments, rotary valves are found on horns, trumpets, trombones, flugelhorns, and tubas. The cornet derived from the posthorn, by applying rotary valves to it in the 1820s in France. An alternative to a rotary valve instrument is the more common piston valve trumpet. However, many European trumpet players tend to favor rotary valves. Trombone F attachment valves are usually rotary, with several variations on the basic design also in use, such as the Thayer axial flow valve and the Hagmann valve. The rotary valve was first applied to the horn in 1824 by Nathan Adams (1783–1864) of Boston and patented in 1835 by Joseph Riedl.
== State and local government == Several states have proposed and passed laws that regulate AI models and AI-generated content, including impersonations, chatbot disclosures, and synthetic political content.
In analogy to digital microelectronics, digital microfluidic operations can be combined and reused within hierarchical design structures so that complex procedures (e.g. chemical synthesis or biological assays) can be built up step-by-step. And in contrast to continuous-flow microfluidics, digital microfluidics works much the same way as traditional bench-top protocols, only with much smaller volumes and much higher automation. Thus a wide range of established chemical procedures and protocols can be seamlessly transferred to a nanoliter droplet format. Electrowetting, dielectrophoresis, and immiscible-fluid flows are the three most commonly used principles, which have been used to generate and manipulate microdroplets in a digital microfluidic device. A digital microfluidic (DMF) device set-up depends on the substrates used, the electrodes, the configuration of those electrodes, the use of a dielectric material, the thickness of that dielectric material, the hydrophobic layers, and the applied voltage.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.